Skip to content

Study · Randomized controlled trial · n = 110 · 2021

2 results

Cerebrolysin Combined with Rehabilitation Enhances Motor Recovery and Prevents Neural Network Degeneration in Ischemic Stroke Patients with Severe Motor Deficits.

Chang WH, Lee J, Shin YI, Ko MH, Kim DY, Sohn MK, Kim J, Kim YH

Journal of personalized medicine11 Jun 2021Cited by 16 (Europe PMC)

PMID34208352 (opens in a new tab)PMCIDPMC8231166 (opens in a new tab)DOI10.3390/jpm11060545 (opens in a new tab)PepBankPUB-34208352
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

The objective of this study was to evaluate whether Cerebrolysin combined with rehabilitation therapy supports additional motor recovery in stroke patients with severe motor impairment. This study analyzed the combined data from the two phase IV prospective, multicenter, randomized, double-blind, placebo-controlled trials. Stroke patients were included within seven days after stroke onset and were randomized to receive a 21-day treatment course of either Cerebrolysin or placebo with standardized rehabilitation therapy. Assessments were performed at baseline, immediately after the treatment course, and 90 days after stroke onset. The plasticity of the motor system was assessed by diffusion tensor imaging and resting state fMRI. In total, 110 stroke patients were included for the full analysis set (Cerebrolysin n = 59, placebo n = 51). Both groups showed significant motor recovery over time. Repeated-measures analysis of varianceshowed a significant interaction between time and type of intervention as measured by the Fugl-Meyer Assessment (p < 0.05). The Cerebrolysin group demonstrated less degenerative changes in the major motor-related white matter tracts over time than the placebo group. In conclusion, Cerebrolysin treatment as an add-on to a rehabilitation program is a promising pharmacologic approach that is worth considering in order to enhance motor recovery in ischemic stroke patients with severe motor impairment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In stroke patients, the Fugl-Meyer Assessment showed a significant interaction between time and treatment.

    In plain wordsIn stroke patients, motor assessment changes depended on time and treatment compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    Direction not reportedFugl-Meyer time-by-treatment interaction
    Study

    n = 110

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · 21 daysAs given in this study (human).

    Measurements

    Full analysis set sample size
    59 patients
    Cerebrolysin
    Full analysis set sample size
    51 patients
    placebo
    p value for Fugl-Meyer time-by-treatment interaction
    < 0.05
    time-by-intervention interaction, Cerebrolysin versus placebo

    Source sentences

    Summary
    Repeated-measures analysis of varianceshowed a significant interaction between time and type of intervention as measured by the Fugl-Meyer Assessment (p < 0.05).
    3 context sentences
    Summary · context
    This study analyzed the combined data from the two phase IV prospective, multicenter, randomized, double-blind, placebo-controlled trials.
    Summary · context
    Stroke patients were included within seven days after stroke onset and were randomized to receive a 21-day treatment course of either Cerebrolysin or placebo with standardized rehabilitation therapy.
    Summary · context
    In total, 110 stroke patients were included for the full analysis set (Cerebrolysin n = 59, placebo n = 51).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In stroke patients, Cerebrolysin reduced degeneration in major motor-related white matter tracts compared with placebo.

    In plain wordsIn stroke patients, Cerebrolysin reduced motor-related white matter degeneration compared with placebo.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMotor white matter degeneration
    Study

    n = 110

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 21 daysAs given in this study (human).

    Source sentences

    Summary
    The Cerebrolysin group demonstrated less degenerative changes in the major motor-related white matter tracts over time than the placebo group.
    3 context sentences
    Summary · context
    This study analyzed the combined data from the two phase IV prospective, multicenter, randomized, double-blind, placebo-controlled trials.
    Summary · context
    Stroke patients were included within seven days after stroke onset and were randomized to receive a 21-day treatment course of either Cerebrolysin or placebo with standardized rehabilitation therapy.
    Summary · context
    In total, 110 stroke patients were included for the full analysis set (Cerebrolysin n = 59, placebo n = 51).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.